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survival outcome. And we found patients with PD-L1 expression and high PLR had the
worst prognosis. The 5-year DFS rates were 68.4%, and 85.8% in high PLRþPD-L1 (þ)
group and low PLRþPD-L1 (-) group respectively (p¼ 0.002). The 5-year OS rates
were 73.4% and 90.1%, respectively (p< 0.001).
Conclusions: High PLR are associated with poor DFS in breast cancer patients. PD-L1
expression combined with high PLR was associated with an aggressive clinical outcome.
Further studies are needed to evaluate the predictive value of combination of PD-L1
and peripheral blood immune markers.
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Background: Breast cancer subtype (BCS) and lymphovascular invasion (LVI) have
both been independently demonstrated as prognostic factors. The objective of this in-
vestigation was to evaluate the prognostic power of LVI and lymph node status among
BCSs.
Methods: From an institutional database, 2017 women with a histopathologically con-
firmed diagnosis of breast cancer treated between January 2006 and December 2014
were consecutively selected for participation in this study.
Results: Of the 2017 patients with breast cancer in the BCS groups, the highest OS and
RFS rates were observed in luminal A subtype (93.6% vs. 95.1%, respectively) and the
lowest were observed in TN subtype (85.3% vs. 83.0%, respectively). There were signifi-
cant differences in OS according to the LVI status between the luminal A, luminal B
and luminal HER2 subtypes. There were also a significant difference in the RFS rate of
the luminal A, luminal B, luminal HER2 and HER2 subgroup. Therefore, we inferred
that there were stronger links with LVI and BCS with regard to OS and RFS rates.
Kaplan-Meier analysis showed that there were significant differences in the OS and RFS
rates according to the LVI status among the BCS groups. There were significant differ-
ences in OS according to the LVI status in the distribution of the luminal A, luminal B,
luminal HER2, and TN subtypes. There were also significant differences in the RFS rates
among the luminal B, luminal HER2, and HER2 subtypes. On multivariate analysis,
after controlling for age, tumor size was independently associated with LVI and lymph
node status among all BCS groups. There were significant differences in OS according
to the status of lymph node-negative and LVI-positive in the luminal HER2 subtype, as
well as lymph node-positive and LVI-positive in the TN subtype. There were also sig-
nificant differences in RFS according to the status of lymph node-negative and LVI-
positive in the luminal A subgroup.
Conclusions: LVI and lymph node status were important prognostic factor for OS and
RFS among all BCSs. In lymph node-negative breast cancer, luminal HER2 had greater
predictive value for OS, whereas luminal A displayed greater predictability for RFS. In
lymph node-positive breast cancer, the TN subtype had greater predictive value for OS.
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Background: Immune system plays an important role in tumor surveillance and es-
cape. Recently tumor infiltrating lymphocytes (TILs) have been proposed as a predict-
ive biomarker for clinical outcome and pathological response (pR) after neoadjuvant
(neoadj) chemotherapy (CT) in breast cancer. PD-L1 is expressed in about 20% of
TNBC, suggesting the possibility of being a therapeutic target for this subtype of can-
cers. Here we studied the association between PD-L1 expression and pR in TNBC.
Methods: We enrolled 54 pts who had received neoadj CT (EC for 4 cycles followed by
Paclitaxel q21 for 4 cycles) between Jan 2008 and Dec 2016 at Policlinico Umberto I
and San Giovanni Hospital of Rome. We performed IHC for CD20, CD3, CD4, CD8,
CD68, N-CAM and PD-L1 (Ventana SP142 clone) in basal paraffin-embedded biop-
sies. PD-L1 expression on tumor cells was evaluated both qualitatively (membrane
staining intensity 0 to 3þ) and quantitatively (% of positive cells.). The percentage of
TILs positive for PD-L1 was also recorded. Statistical analysis was performed with T di
Student test and v2 test.
Results: We enrolled 54 pts (median age: 50 y; range 28-75) affected by TNBC: 51 duc-
tal (94.4%), 2 metaplastic (3.7%), 1 lobular (1.9%). The clinical stage before neoadj CT
was as follow: 12.9% cT1 (7 pts), 72.2% cT2 (39 pts), 3.7% cT3 (2 pts), 1.85% cT4
(1 pt) and 5.5% cTx (3 pts). 23 pts were cNþ (42.5%). After neoadj CT 30 pts under-
went mastectomy (55%) and 24 conservative surgery (45%). 19 pts (35%) showed
pCR. No significant associations were found between pR and cT, cN, age, histotype and
KI-67. In 64.8% of basal biopsies (35 pts) PD-L1 was not detected on tumor cells and in
18.5% (10 pts) it was absent in the immune infiltrate. PD-L1 expression was detected
in> 25% of tumor cells in 4 pts, all of which showed pCR (p¼ 0.024). No associations
between intensity of membrane staining and pR were detected (p¼ 0.7). The immune
infiltrate was characterized mostly by the presence of CD3þCD8þ. No statistically sig-
nificant associations between and PD-L1 expression on immune infiltrate were
detected.
Conclusions: Basal PD-L1 expression on cancer cells was associated with a better pR in
TNBC undergoing neoadj CT. The introduction of anti PD-1/PD-L1 therapy in this
setting of pts could lead to interesting results.
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Background: Assessment of tumor infiltrating lymphocytes (TIL) by pathologists using
Hematoxylin-Eosin (H&E), has been described as a prognostic factor in resected
NSCLC. We aimed to correlate TIL to the benefit from nivolumab in patients (pts)
with treated advanced NSCLC.
Methods: Patients with advanced NSCLC treated with nivolumab, with biopsy avail-
able for evaluation, were included between November 2012 and February 2017 in two
cancer centers. Patients characteristics and outcome were collected. The percentage of
tumor infiltrating lymphocytes in the stroma was evaluated using H&E staining from
archival pretreatment tumor tissue samples. Primary endpoint was to correlate TIL
density with progression free survival (PFS).
Results: Out of ninety-eight patients included. 60 (61%) pts were male, with median
age of 61 years and 85 (89%) were smokers. Sixty three (73%) pts were PS 0-1. Sixty
tumors (61%) were adenocarcinoma, 29 (30%) squamous and 9 (10%) other histolo-
gies. Among 83 tumors with known molecular profile, 22 (27%) were KRAS mutated 7
(8%) EGFR mutated, 1(1%) ALK positive. The median treatment line was 3 (2-4). The
median follow up was 8 months (m)(95%CI[6-19]). The median PFS was 2 m
(95%CI[1-5]). The ORR was for 16%. The median TIL density was 5% (2-15). TIL
density5% correlated with PFS in univariate and multivariate analysis (HR: 0.48
[0.28-0.82] p¼ 0.007 and HR:0.31 [0.14-0.68] p¼ 0.004 respectively). TIL density
5% was also associated with better ORR (OR¼ 3.5, 95%CI [1.06-11.7], p¼ 0.04).
Conclusions: Pathological assessment of TIL allows an easy evaluation of immune in-
filtration in NSCLC and independently correlates PFS in NSCLC pts treated with nivo-
lumab. Results from validation cohorts and combination with other morphological
and immunohistochemical parameters will be reported.
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Background: Cancer-associated inflammation is a key molecular feature of PC and
may affect the clinical course. The aim of this study was to evaluate the prognostic rele-
vance of SIRI based on peripheral neutrophil, monocyte, and lymphocyte counts in
metastatic PC and its association with the metastatic site.
Methods: Retrospective analysis of the medical records of patients with pathologically
confirmed metastatic PC between January 2011 and December 2016. Patients were clas-
sified as having liver metastases (LM) or extrahepatic metastases alone (EM).
Associations with overall survival (OS) were analyzed using Cox proportional models.
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